Tag: 300-400

Hashem, F. M.; Sakran, W. S.; Shaker, D. S. published an article in 2003, the title of the article was Ocular bioavailability of ciprofloxacin hydrochloride from certain ophthalmic preparations.Application of 86393-32-0 And the article contains the following content:

The bioavailability of ciprofloxacin hydrochloride (CPX-HCl) in eye tissues and aqueous humor of rabbits was studied. The selected ophthalmic preparations were ophthalmic solution (eye drops) containing hydroxy Pr Me cellulose (HPMC), ophthalmic gels prepared with HPMC or Me cellulose (MC) or sodium alginate. Ocular inserts were prepared from HPMC, or MC or Eudragit RS. The time for peak concentration (tmax) of the drug in the eye tissues and aqueous humor was attained after one hour from the ophthalmic solution, while it was two hours in case of ophthalmic gels irresp. to polymer type. Ocular inserts prepared from HPMC or MC also showed peak concentration time of two hours after application in the rabbit’s eyes. However, the tmax was reached after three hours from Eudragit RS ocular inserts. In all tested ophthalmic formulations. CPX-HCL was available in conjunctiva in a higher concentration than in the cornea, while iris-ciliary body and aqueous humor showed less drug concentration at all time intervals. The corneal drug bioavailability represented by the area under the curve (AUC)0-5 was greatly improved after the application of ocular inserts than other forms (solution or gel). Thus Eudragit RS ocular inserts showed the highest level of the drug bioavailability in eye tissues and aqueous humor due to prolonged retention time, whereas ophthalmic solution was rapidly uptaken and eliminated by tears from eye tissues. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Application of 86393-32-0

The Article related to ciprofloxacin ophthalmic ocular bioavailability, Pharmaceuticals: Formulation and Compounding and other aspects.Application of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On May 1, 2003, Gusler, Gloria; Berner, Bret; Chau, Mei; Padua, Aimee published a patent.Safety of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate The title of the patent was Optimal polymer mixtures for gastric retentive tablets. And the patent contained the following:

Unit dosage form tablets for the delivery of pharmaceuticals are formed of the pharmaceutical dispersed in a solid unitary matrix that is formed of a combination of PEG and hydroxypropyl Me cellulose. The combination offers unique benefits in terms of release rate control and reproducibility while allowing both swelling of the tablet to effect gastric retention and gradual disintegration of the tablet to clear the tablet from the gastrointestinal tract after release of the drug has occurred. Thus, tablets contained gabapentin 60.0,,PEG 24.3, HPMC 14.7, and Mg stearate 1.0%. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Safety of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

The Article related to polymer mixture gastric retentive tablet, Pharmaceuticals: Formulation and Compounding and other aspects.Safety of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On February 27, 2008, Amirov, N. K.; Egorova, S. N.; Akhmetova, T. A.; Fedorov, A. A.; Galiullina, T. N.; Karipova, R. M.; Stepanova, N. V. published a patent.Recommanded Product: 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate The title of the patent was Composition and method for preparing ciprofloxacin ophthalmic ointment. And the patent contained the following:

The invention proposes an ophthalmic ointment containing ciprofloxacin hydrochloride monohydrate equivalent to the concentration 0.1-0.9% as a free base, a preserving agent, for example nipagin or nipasol, and a sterile base consisting of vaseline melt of sort “”for ophthalmic ointments”” and anhydrous lanolin. The ophthalmic ointment is prepared by melting vaseline and anhydrous lanolin and step-by-step mixing milled ciprofloxacin hydrochloride and the preserving agent with sterile base. The invention provides producing a sterile and stable ciprofloxacin-containing ophthalmic ointment used for local treatment of eye inflammatory diseases and of bacterial etiol. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Recommanded Product: 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

The Article related to eye ointment ciprofloxacin formulation, Pharmaceuticals: Formulation and Compounding and other aspects.Recommanded Product: 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On February 22, 2001, Fekete, Pal; Fellner, Gyorgy, Mrs.; Gora, Laszlo, Mrs.; Jambor, Istvan, Mrs.; Feikus, Szilvia; Palfi, Zoltan, Mrs.; Zsigmond, Zsolt published a patent.Recommanded Product: 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate The title of the patent was Ciprofloxacin-containing pharmaceutical composition and process for the preparation thereof. And the patent contained the following:

The invention relates to an immediate-release pharmaceutical composition containing ciprofloxacin, a binder, disintegrating agent and optionally further pharmaceutical auxiliary agents. The composition comprises 60-80 % of ciprofloxacin (in the form of ciprofloxacin hydrochloride monohydrate), 2-10 % of maltodextrin, 5-15 % of a disintegrating agent of carboxymethyl starch type, 3-6 % of silica, 1-3 % of a lubricant and optional 2-6 % of a film-coating layer for film-coated tablets. A tablet contained ciprofloxacin hydrochloride monohydrate 582, Na CM starch 82, maltodextrin 40, silica 40, Mg stearate 6, and Opadry Y-1-7000 16 mg. The tablet was dissolved in the amounts of 94.3, 95.4, and 98.5 % in 5, 15, and 30 min, resp. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Recommanded Product: 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

The Article related to immediate release tablet ciprofloxacin, Pharmaceuticals: Formulation and Compounding and other aspects.Recommanded Product: 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On December 31, 2008, Pastini, Ana C.; Faour, Joaquina; Vergez, Juan A.; Ricci, Marcelo A.; Fischbein, Gustavo A. published a patent.Recommanded Product: 86393-32-0 The title of the patent was A rupturing controlled release device comprising a subcoat. And the patent contained the following:

The present invention provides a simple and improved rupturing controlled release device that is capable of providing a controlled release of active agent contained in the core first through a preformed passageway and then through an in situ formed second passageway into an environment of use in a standardized release profile manner. The rupturing controlled release device comprises a core comprising at least one drug and at least one osmopolymer, a semipermeable membrane enclosing the core and having at least one preformed passageway there through, wherein the semipermeable membrane ruptures during use to form a second passageway in the semipermeable membrane at a location spaced away from the preformed passageway, and a release-controlling subcoat between the core and the semipermeable membrane. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Recommanded Product: 86393-32-0

The Article related to controlled release delivery rupturing, Pharmaceuticals: Formulation and Compounding and other aspects.Recommanded Product: 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On March 28, 2002, Singh, Onkar N.; Bhagat, Haresh G.; Kabra, Bhagwati P. published a patent.Category: piperazines The title of the patent was Topical composition comprising ciprofloxacin and hydrocortisone. And the patent contained the following:

This invention is directed toward a topical composition comprising ciprofloxacin and hydrocortisone, where the composition contains a specific grade of poly(vinyl alc.) as a viscosity augmenter. The specified grade of polyvinyl alc. is 85-90% hydrolyzed poly(vinyl alc.). Thus, a composition contained ciprofloxacin-HCl monohydrate 0.35, micronized hydrocortisone 1.9, benzyl alc. 0.9, NaCl 0.9, sodium acetate trihydrate 0.68, acetic acid 0.255, Phospholipon 90H 0.15, Polysorbate-20 0.10, NaOH and/or HCl to pH 4.7, and water to 100%. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Category: piperazines

The Article related to topical ciprofloxacin hydrocortisone, Pharmaceuticals: Formulation and Compounding and other aspects.Category: piperazines

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On February 20, 1997, Canovas Soler, Pedro; Delgadillo Duarte, Joaquin; Moreno Rueda, Juan published a patent.Category: piperazines The title of the patent was Aqueous compositions containing ciprofloxacin. And the patent contained the following:

Aqueous compositions for treatment of otitis media with perforation of the tympanic membrane contain the broad-spectrum antibiotic ciprofloxacin.HCl.H2O 0.12-0.6 (equivalent to 0.1-0.5% free base), buffer (pH 4-5) 0.5-3.0, nonionic surface-active agent 0.05-0.3, thickening agent 0.5-2.0 g, and H2O to 100 mL. This solution is packaged in sterile single dosage units without preservatives. Thus, an aqueous solution was prepared containing ciprofloxacin.HCl.H2O 0.40, AcOH 0.45, NaOAc.3H2O 1.20, polysorbate 80 0.19, methylcellulose 1.15, and glycerin 1.62 weight%. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Category: piperazines

The Article related to ciprofloxacin solution otitis media, Pharmaceuticals: Formulation and Compounding and other aspects.Category: piperazines

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On March 20, 2005, Pshenichnikov, V. G.; Frolova, L. V.; Zaripova, Z. I.; Dmitrieva, I. M.; Besh, E. A.; Mokhnacheva, E. V.; Anishchenko, S. S.; Predeina, N. I. published a patent.Category: piperazines The title of the patent was Eye drops and method for obtaining them. And the patent contained the following:

The present innovation deals with medicinal preparations designed as solution and indicated for therapeutic needs. Eye drops contain ciprofloxacin hydrochloride monohydrate equivalent to 0.3% free base, a buffer system that keeps pH within 3.5-5.5 interval, as a conserving agent – benzalkonium chloride and as a stabilizer – the salt of disodium ethylenediamine tetraacetic acid; moreover, their range of osmolality values correspond to 150-450 mM/kg H2O. Eye drops should be obtained by preparing a buffer system in which mannitol should be dissolved followed by the salt of disodium ethylenediamine tetraacetic acid, benzalkonium chloride, and ciprofloxacin hydrochloride. Then one should perform the control for the quality of the obtained solution, which then is filtered by applying sterilizing elements and packed. This innovation provides treatment of eyes at certain desired osmolality. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Category: piperazines

The Article related to eye drop ciprofloxacin formulation, Pharmaceuticals: Formulation and Compounding and other aspects.Category: piperazines

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On July 17, 2001, Lee, Fang-yu published a patent.Quality Control of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate The title of the patent was Oral antimicrobial formulations of ciprofloxacin. And the patent contained the following:

The invention provides 3 oral ciprofloxacin formulations, with the first formulation comprising 60-75% ciprofloxacin or its salt, 0.3-10% pregelatinized starch as binder, 5-30% lactose as diluent, 1-10% of sodium starch glycolate as disintegrant and 0.5-2% magnesium stearate as lubricant. The second formulation comprises 60-75% ciprofloxacin or its salt, 1-5% polyvinylpyrrolidone as binder, 5-30% lactose as diluent; 1-10% sodium starch glycolate as disintegrant, and 0.5-2% magnesium stearate as lubricant. The third formulation comprises 60-75% ciprofloxacin or salt, 1-8% poly(vinyl alc.) as binder, 5-30% lactose as diluent, 1-10% sodium starch glycolate as disintegrant, and 0.5-2% magnesium stearate as lubricant. The ciprofloxacin, the binder, the diluent, the disintegrant, and the lubricant are first mixed in a dry state to form a powder mixture, followed by mixing with a water-solvent solution to convert the dry powder mixture into a wet powder mixture before grinding and granulating the wet powder mixture into wet granules, which are further dried to form dry granules. The above 3 formulations do not contain cellulose. Thus, tablets contained ciprofloxacin 70, PVP-K30 2, sodium starch glycolate 5, lactose 21, and Mg stearate 2%. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Quality Control of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

The Article related to antimicrobial ciprofloxacin oral, Pharmaceuticals: Formulation and Compounding and other aspects.Quality Control of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On March 31, 2000, Tsvetkov, Plamen K.; Velikova, Evtimija I; Kafedzhiiski, Stefan K.; Stoyanov, Simeon I; Dimitrova, Silvija S.; Evstatieva, Anka V; Stoyanova, Evgenija K. published a patent.SDS of cas: 86393-32-0 The title of the patent was Composition and method for the preparation of a medicament dosage form. And the patent contained the following:

The invention relates to a composition and method for the preparation of a medicament form based on 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-1-(1-piperazinyl)-quinolin-3-carboxylic acid monohydrochloride, known as ciprofloxacin, which is applied as antibacterial medicine in the medical practice. The composition includes: ciprofloxacin hydrochloride monohydrate and lactose monohydrate in ratio 4.93:1, mannitol SD 200, microcrystalline cellulose, sodium starch glycolate, colloid silicon dioxide, talcum and magnesium stearate. The medicamentous form is produced when ciprofloxacin and lactose monohydrate are mixed in a mixer granulator and are homogenized at speeds: 98 r.p.m. for the small blade, and 1500 r.p.m. for the large blade. Sep., the dissolved sodium starch glycolate is added at continuous agitation to the homogenized mixture Granular mass is produced which is dried at 45-50°C to residual moisture of 3% and is calibrated. To the dry granular mass mannitol SD 200, microcrystalline cellulose, sodium starch glycolate, colloid silicon dioxide, talcum and magnesium stearate. The medicamentous form is produced when ciprofloxacin and lactose monohydrate are mixed in a mixer granulator and are homogenized at speeds: 98 r.p.m. for the small blade, and 1500 r.p.m. for the large blade. Sep., the dissolved sodium starch glycolate is added at continuous agitation to the homogenized mixture Granular mass is produced which is dried at 45-50°C to residual moisture of 3% and is calibrated. To the dry granular mass mannitol SD 200, microcrystalline cellulose, colloidal silicon dioxide, talcum and magnesium stearate are added. The mixture produced is homogenized. A water impermeable layer of a film with Opadry is applied. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).SDS of cas: 86393-32-0

The Article related to ciprofloxacin dosage film tablet, Pharmaceuticals: Formulation and Compounding and other aspects.SDS of cas: 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics